Eris Lifesciences Reports Q3 FY26 Unaudited Financial Results
Eris Lifesciences reported Q3 FY26 consolidated net profit of ₹108.83 crore, up from ₹87.06 crore in Q3 FY25. Nine-month consolidated profit was ₹368.40 crore. Standalone Q3 profit was ₹3.09 crore. The company made an exceptional provision of ₹17.24 crore due to new labor codes. Swiss Parenterals became a wholly owned subsidiary on January 16, 2026.
The results show growth in profits, which is a positive indicator for investors. The acquisition of Swiss Parenterals strengthens the company's structure. However, the exceptional item impacts the standalone profit, and the overall impact is moderate.
The consolidated net profit for the quarter and nine months shows an increase compared to the previous year, indicating positive financial performance. The acquisition making Swiss Parenterals a wholly owned subsidiary is a strategic positive move.
Eris Lifesciences Limited announced its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The Board of Directors approved and took on record these financial results, along with the limited review report, which was issued with an unmodified opinion.
The meeting of the Board of Directors commenced at 11:30 AM and concluded at 01:10 PM on Friday, February 13, 2026. The company also provided details as per Regulation 52(4) of SEBI Listing Regulations.
In its standalone financial results for the quarter ended December 31, 2025, Eris Lifesciences reported a net profit of ₹3.09 crore. For the nine-month period ended December 31, 2025, the standalone net profit stood at ₹252.65 crore. The consolidated financial results for the quarter ended December 31, 2025, showed a net profit of ₹108.83 crore, and for the nine months ended December 31, 2025, the consolidated net profit was ₹368.40 crore. An exceptional item of ₹14.67 crore was recorded in standalone results and ₹17.24 crore in consolidated results, primarily due to the financial implications of India's new Labour Codes impacting gratuity and leave liabilities.
Subsequent to the quarter, on January 16, 2026, the company completed the acquisition of the remaining 30% stake in Swiss Parenterals Limited through a preferential allotment, making it a wholly owned subsidiary. The company also announced a Composite Scheme of Arrangement for the amalgamation of AHL with ETL, subject to regulatory approvals.
What to do with a filing like this
Eris Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Eris Lifesciences Limited. Read the original for the full detail.